Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Recent Advances in the Treatment of Scleroderma, March 13, 2020, 3/13/2020 8:00:00 AM - 3/13/2023 9:00:00 AM, Dr. Simms reviews the pathophysiology and clinical features of limited and diffuse scleroderma, focusing primarily on pulmonary artery hypertension (PAH) and interstitial lung disease (IDL) complications in this enigmatic disease. Investigating the mechanisms of action in PAH and ILD have led to effective combination therapies and lower mortality, although several of the current treatments have challenging toxicities. Potential future directions include the use of cannabinoids and stem cell transplantation.
Presenter
Robert W. Simms, MD
Emeritus Professor of Medicine, Boston University School of Medicine
Professor, Department of Medicine
Geisel School of Medicine at Dartmouth
Dartmouth-Hitchcock Medical Center
About our Presenter
Dr. Simms was the Clinical Director and Fellowship Program Director at Boston University before becoming the Section Head from 2008-2018. He joined the faculty of the Geisel School of Medicine at Dartmouth in 2020. His guiding principle for developing the most successful center of disease investigation was the creation of a highly collaborative environment, which included both basic and clinical investigators under one roof. This model has remained a highly productive template for the Scleroderma Center at Boston University, which has become among the largest and most successful scleroderma centers both nationally and internationally.
Learning Outcome(s)
Participants will be able to review the principle clinical features which define scleroderma, discuss the impact of new therapies on the current management of scleroderma and outline the future pipeline of scleroderma therapies.
Disclosure
In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.
The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for Recent Advances in the Treatment of Scleroderma, March 13, 2020 (Medicine Grand Rounds) have reported the following financial interest or relationship* with various companies/organizations. The Activity Director and Planning Committee member roles were resolved by altering the individual’s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. The speaker conflicts have been resolved by validating the activity content through independent peer review by Kelly Kieffer, MD. All potential conflict(s) were resolved.
* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio.
* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and is on the Scientific Advisory Board for Allurion.
* Robert W. Simms, MD ~ has grant/research support from Actelion, Novartis, Gilead, Genzyme, MedImmune, Cytori, Boehringer Ingelheim, EMD Serono, Bristol-Myers Squibb, and Genentech.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.
*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.
Presenter
Robert W. Simms, MD
Emeritus Professor of Medicine, Boston University School of Medicine
Professor, Department of Medicine
Geisel School of Medicine at Dartmouth
Dartmouth-Hitchcock Medical Center
About our Presenter
Dr. Simms was the Clinical Director and Fellowship Program Director at Boston University before becoming the Section Head from 2008-2018. He joined the faculty of the Geisel School of Medicine at Dartmouth in 2020. His guiding principle for developing the most successful center of disease investigation was the creation of a highly collaborative environment, which included both basic and clinical investigators under one roof. This model has remained a highly productive template for the Scleroderma Center at Boston University, which has become among the largest and most successful scleroderma centers both nationally and internationally.
Learning Outcome(s)
Participants will be able to review the principle clinical features which define scleroderma, discuss the impact of new therapies on the current management of scleroderma and outline the future pipeline of scleroderma therapies.
Disclosure
In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.
The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for Recent Advances in the Treatment of Scleroderma, March 13, 2020 (Medicine Grand Rounds) have reported the following financial interest or relationship* with various companies/organizations. The Activity Director and Planning Committee member roles were resolved by altering the individual’s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. The speaker conflicts have been resolved by validating the activity content through independent peer review by Kelly Kieffer, MD. All potential conflict(s) were resolved.
* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio.
* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and is on the Scientific Advisory Board for Allurion.
* Robert W. Simms, MD ~ has grant/research support from Actelion, Novartis, Gilead, Genzyme, MedImmune, Cytori, Boehringer Ingelheim, EMD Serono, Bristol-Myers Squibb, and Genentech.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.
*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.
